Buprenorphine for Suicidal Ideation

Phase-Based Progress Estimates
New York State Psychiatric Institute, New York, NY
Suicidal Ideation+3 More
Belbuca Buccal Product - Drug
All Sexes
What conditions do you have?

Study Summary

This study aims to examine the effect of low-dose buprenorphine as an add-on to treatment-as-usual for suicidal ideation in individuals with major depression, and investigate the functional brain activity related to its potential anti-suicidal effect.

Eligible Conditions

  • Suicidal Ideation
  • Major Depressive Disorder (MDD)

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Suicidal Ideation

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 2 Weeks

2 Weeks
Changes in Beck Scale for Suicidal Ideation (SSI) scores from pre- to Week 2 post-treatment.
Changes in functional magnetic resonance imaging (fMRI) blood oxygen- level dependent (BOLD) signal in the amygdala in response to negative vs. neutral pictures from pre- to Week 2 post-treatment

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Suicidal Ideation

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

30 Total Participants · 2 Treatment Groups

Primary Treatment: Buprenorphine · Has Placebo Group · Phase 3

Experimental Group · 1 Intervention: Belbuca Buccal Product · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 weeks

Trial Background

Prof. Mina.Rizk, Assistant professor
Principal Investigator
New York State Psychiatric Institute
Closest Location: New York State Psychiatric Institute · New York, NY
Photo of New York  1Photo of New York  2Photo of New York  3
2001First Recorded Clinical Trial
4 TrialsResearching Suicidal Ideation
212 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to comply with all study procedures and are available for the duration of the study.
You have a current major depressive episode.\n
You are taking an antidepressant medication regimen that includes an adequate dose of an antidepressant for at least the past 4 weeks.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.